Vernakalant (oral) prevention of atrial fibrillation recurrence post-conversion study.
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2017
At a glance
- Drugs Vernakalant (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Cardiome Pharma
- 31 Aug 2009 Results reported at the European Society of Cardiology (ESC) annual meeting.
- 14 Jul 2008 Final results reported by Cardiome.
- 14 Jul 2008 Status changed from in progress to completed as reported by Cardiome.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History